- Home
- Â /Â Bicycle Therapeutics
Bicycle Therapeutics
Stock Price
$24.5
2024-10-29
Market Capitalization
$1.7 B
2024-10-29
Revenue
$72.6 M
FY, 2025
Bicycle Therapeutics Summary
Company Summary
- Overview
- Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops cancer therapies. It offers bicyclic peptide technology, immuno-oncology, radio, and toxin conjugate pipelines.
- Type
- Public
- Status
- Active
- Founded
- 2009
- HQ
- Cambridge, GB | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Michael Skynner, Chief Technology Officer
Nigel Crockett, Chief Business Officer
Alistair Milnes, Chief Operating Officer
Operating MetricsView all
Patents
103
4.6%
FY, 2021
Trademarks
46
FY, 2021
LocationsView all
2 locations detected
Cambridge, England HQ
United Kingdom
Blocks A & B Portway Building, Granta Park
Cambridge, MA
United States
35 Cambridgepark Dr
Bicycle Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $887.0K
- Net income (Q1, 2026)
- ($60.8M)
- Cash (Q1, 2026)
- $559.5M
- EBIT (Q1, 2026)
- ($65.5M)
- Enterprise value
- $1.2B